JNJ vs UTHR

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

United Therapeutics continues to build on its strong foundation in rare pulmonary diseases with significant recent wins. The TETON-1 pivotal study success for Tyvaso in IPF substantially expands its addressable market and derisks future revenue streams from its core business. Furthermore, the FDA's RMAT designation for miroliverELAP provides a positive signal for its ambitious regenerative medicin...